Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 271

Sort by

Sort Order Select

Journal Articles

Safety and efficacy of surovatamig (AZD0486) in adolescent and adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Updated Results from the Phase 1/2 SYRUS study

Blood (2025) 146 (Supplement 1): 3345.

https://doi.org/10.1182/blood-2025-3345

Published: 2025

Journal Articles

Excellent prognosis for adult patients with Philadelphia chromosome-negative ALL with standard genetic risk and EARLY clearance of MRD. sub-analysis of pethema LAL19 trial

Anna Torrent, Mireia Morgades, Susana Barrera, Jordi Ribera, Eulàlia Genescà, José González-Campos, Nuria Martinez-Cibrian, Pau Montesinos, Alberto Hernández-Sánchez, Pere Barba, Edgar Zapico, Ricardo Sanchez, Marta Sitges Arriaga, Clara Maluquer Artigal, Esperanza Such, Carmen Botella, Maria Queipo De Llano, Mónica Cabrero Calvo, Ana Maria Vicent Castelló, Paula Lopez de Ugarriza, Mar Tormo, Bernardo Gonzalez Gonzalez, Irene García-Cadenas, Carlos Rodriguez Medina, Pilar Martínez-Sánchez, Arancha Bermúdez, Ignacio Gómez-Centurión, María Herrero García, Juana Ciudad, María Hermosín-Ramos, Josefina Serrano, Jose Angel Raposo Puglia, Laura Solán Blanco, Verónica Roldán Galiacho, María Almudena De Laiglesia Lorenzo, Lucía Gómez Pérez, María Solé Rodriguez, Mará Sol Casado Calderón, Laura Llorente González, Daniel Barrios Decoud, Ferran Vall-Llovera Calmet, Lorenzo Algarra, María Lourdes Amador Barciela, Raimundo Garcia, Antonia Cladera Serra, Juan Miguel Bergua Burgues, Isabel Granada, Jesus Maria Hernandez Rivas, Alberto Orfao, Josep-Maria Ribera

Blood (2025) 146 (Supplement 1): 1564.

https://doi.org/10.1182/blood-2025-1564

Published: 2025

Journal Articles

Clinical impact of FLT3 microclones on outcomes in patients with newly diagnosed FLT3-ITD negative AML: A subanalysis from the pethema quiwi trial

Blood (2025) 146 (Supplement 1): 1719.

https://doi.org/10.1182/blood-2025-1719

Published: 2025

Journal Articles

Real-world insights into venetoclax and/or hypomethylating agent discontinuation in patients with Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 5232.

https://doi.org/10.1182/blood-2025-5232

Published: 2025

Journal Articles

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data

Blood (2025) 146 (Supplement 1): 5230.

https://doi.org/10.1182/blood-2025-5230

Published: 2025

Journal Articles

Identifying patients with indolent Acute Myeloid Leukemia: Long term survivors after best supportive care only, results from the pethema registry

Jorge Labrador, David Martinez-Cuadron, Cristina Gil, Mar Tormo, Josefina Serrano, Pilar Martinez Sanchez, Eduardo Rodríguez-Arbolí, Jose-Mario Mariz, Fernanda Trigo, Teresa Bernal Del Castillo, Juan Miguel Bergua Burgues, Carlos Rodríguez-Medina, Olga Salamero, Joana Brioso Infante, Juan Manuel Alonso-Dominguez, Pilar Herrera Puente, María Luz Amigo, Susana Vives, Raimundo García-Boyero, Lorenzo Algarra, Mercedes Colorado, Monica Romero, Claudia Sossa, Maria Vidriales Vicente, Armando Mena Duran, Celina Benavente, Esperanza Lavilla-Rubira, Maria Jose Sayas Lloris, Emília Cortesão, Veronica Lizama, Olga Arce-Fernández, María García-Fortes, Maria Dolores Madrigal, Manuel Perez Encinas, Marta Valero-Nuñez, Luis Felipe Casado Montero, Maria Teresa Olave Rubio, Ágata Almela, Diana Cuervo, Victor Noriega Concepción, Marcela Espinoza, Beatriz De Rueda Ciller, Manuel Barrios García, Rosa Fernández, Bernardo González González, Carmen Montes, Christine Rojas, Esther Pérez-Santaolalla, María Lourdes Amador Barciela, ANA Yurena Oliva Hernandez, Rebeca Rodriguez-Veiga, Isabel Cano, Evelyn Acuña-Cruz, Antonio Solana-Altabella, Pau Montesinos

Blood (2025) 146 (Supplement 1): 875.

https://doi.org/10.1182/blood-2025-875

Published: 2025

Journal Articles

Crenolanib plus salvage chemotherapy improves outcomes in FLT3-mutant and NPM1 co-mutated relapsed/ refractory (R/R) Acute Myeloid Leukemia (AML): Results from a randomized, placebo-controlled, double-blind trial

Thomas Cluzeau, Pierre Yves Dumas, Pau Montesinos, Gaia Ciolli, Céline Berthon, Felicetto Ferrara, Adriano Venditti, José Antonio Pérez-Simón, Maria Calbacho, Richard Noppeney, Monia Lunghi, Chiara Cattaneo, Fabrizio Pane, Francesco Lanza, Juan Miguel Bergua Burgues, Alessandro Isidori, Yngvar Floisand, Vinay Jain, Eunice Wang

Blood (2025) 146 (Supplement 1): 767.

https://doi.org/10.1182/blood-2025-767

Published: 2025

Journal Articles

Monotherapy update from Phase 1 portion in Phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia

Blood (2025) 146 (Supplement 1): 763.

https://doi.org/10.1182/blood-2025-763

Published: 2025

Journal Articles

Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 651.

https://doi.org/10.1182/blood-2025-651

Published: 2025

Journal Articles

Impact of molecular profile and variant allele frequency in patients with Acute Myeloid Leukemia undergoing allogeneic transplantation in first remission: A study by the pethema group

Rafael Colmenares, Eva Barragán, Rebeca Rodriguez-Veiga, Laura Torres-Miñana, Joaquín Sánchez-García, Mar Tormo, Teresa Bernal Del Castillo, Pilar Martinez Sanchez, Eduardo Rodríguez-Arbolí, Cristina Gil, Elena Soria-Saldise, Josefina Serrano, Mercedes Colorado, María García-Fortes, Cristina Bilbao, José Luis López Lorenzo, Maria Jose Larrayoz, Esther Pérez-Santaolalla, Esperanza Lavilla-Rubira, Lorenzo Algarra, Maria Carmen García-Garay, Carmen Chillon, Melissa Torres-Ochando, Raimundo García-Boyero, Carmen Couto, Ágata Almela, Victor Noriega Concepción, Marta Callejas, Manuel Barrios García, Soledad Casado, Amaia Balerdi Malcorra, Ana Cabello, Jorge Labrador, María Carmen Mateos, María Luz Amigo, Manuel Pérez-Encinas, Maria Jose Garcia, Lisette Costilla-Barriga, Juan Miguel Bergua Burgues, Gonzalo Carreño, Joaquin Martinez-Lopez, Rosa Ayala Diaz, Pau Montesinos

Blood (2025) 146 (Supplement 1): 6998.

https://doi.org/10.1182/blood-2025-6998

Published: 2025

Journal Articles

CYP3A4 inhibitors (CYP3A4i) and myelosuppression in patients (Pts) with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) in the phase 3 AGILE study

Andre Schuh, Pau Montesinos, Christian Recher, Michael Heuser, Susana Vives, Ewa Zarzycka, Marta Riva, Rodrigo Calado, Su-Peng Yeh, Courtney DiNardo, Mohammad Hossain, Jianan Hui, Diego Gianolio, Assaf Vestin, Rui Ding, Prapti Patel, Stéphane De Botton, Hartmut Döhner, Jianxiang Wang

Blood (2025) 146 (Supplement 1): 3440.

https://doi.org/10.1182/blood-2025-3440

Published: 2025

Journal Articles

Analysis of hematologic improvement (HI) by time to response in Relapsed/Refractory Acute Myeloid Leukemia (AML) patients treated with olutasidenib

Shira Dinner, Brian Jonas, Antonio Curti, Stephane De Botton, Pau Montesinos, Karen W.L. Yee, Gail Roboz, William Blum, Gary Schiller, Jorge Cortes, Justin Watts, Andrew Wei, Aaron Sheppard, Hua Tian, Eunice Wang

Blood (2025) 146 (Supplement 1): 3439.

https://doi.org/10.1182/blood-2025-3439

Published: 2025

Journal Articles

Real world outcomes in 355 patients with Acute Myeloid Leukemia arising from chronic myelomonocytic leukemia: A multinational retrospective study

Laura Cicconi, Jad Othman, Alessandra Spagnoli, Enrico Attardi, Eleonora De Bellis, Pilar Lloret Madrid, Tamara Castaño, Juan Miguel Bergua Burgues, Arianna Savi, Ida Carmosino, Roberta Mazzarella, Armando Mena Duran, Mar Tormo, Susana Vives, Emília Cortesão, Fernanda Trigo, Mercedes Colorado, Lorenzo Algarra, Olga Salamero, José Antonio Pérez-Simón, Esther Perez, ANA Yurena Oliva Hernandez, Teresa Bernal Del Castillo, Pilar Martinez Sanchez, Claudia Lucia Scossa Melo, Cristina Gil, Marta Valero Núñez, Luis Felipe Casado Montero, Teresa Olave, Maria Vidriales Vicente, Carla Amigo, Irene Navarro Vicente, Cristian Escolano Escobar, Pilar Herrera Puente, Kenny Galvez, Rosalia Riaza Grau, Annalina Piccioni, Davide Facchinelli, Enrico Santinelli, Raffaele Palmieri, Giovanni Luzi, Monica Piedimonte, Sabrina Mariani, Luana Fianchi, Carmela Gurrieri, Ilaria Tanasi, Davide Lanzarotto, Fabio Guolo, Salvatore Perrone, Elisabetta Todisco, Anjum Khan, Victoria Campbell, Maria Teresa Voso, Daniela Cilloni, Adriano Venditti, Roberto Latagliata, Richard Dillon, Massimo Breccia, Luca Maurillo, Susanna Fenu, Alessandro Pulsoni, Pau Montesinos

Blood (2025) 146 (Supplement 1): 3437.

https://doi.org/10.1182/blood-2025-3437

Published: 2025

Journal Articles

Phase 1 study of revumenib in combination with intensive chemotherapy (IC) in patients (Pts) with newly diagnosed (ND) Acute Myeloid Leukemia (AML) harboring genetic alterations in KMT2A, NPM1, or NUP98: SNDX-5613-0708

Ibrahim Aldoss, Carl Shultz, Bradley Hunter, David Swoboda, Pau Montesinos, Sarit Assouline, Shaun Fleming, Carolyn Grove, Andre Schuh, David Taussig, Karla Malloy, Enoch Cobbina, Jingshan Zhang, Mila Ayash-Rashkovsky, Jessica Clement, Eytan Stein, John DiPersio

Blood (2025) 146 (Supplement 1): 3425.

https://doi.org/10.1182/blood-2025-3425

Published: 2025

Journal Articles

Preliminary results from RIVER-81, a phase 2 study of romaciclib (RVU120) + venetoclax in patients with acute myeloid leukemia failing first-line venetoclax + hypomethylating agent (HMA)

Blood (2025) 146 (Supplement 1): 3424.

https://doi.org/10.1182/blood-2025-3424

Published: 2025

Journal Articles

Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study

Blood (2025) 146 (Supplement 1): 3418.

https://doi.org/10.1182/blood-2025-3418

Published: 2025

Journal Articles

Disease presentation and immunophenotype characteristics in 257 patients with blastic plasmacytoid dendritic cell neoplasm: A pethema/PALG study

Beatriz Martín Herreros, Irene Navarro Vicente, Milena Sitkiewicz, Pilar Lloret Madrid, Łukasz Targoński, Amparo Sempere, Joaquín Sánchez-García, Josefina Serrano, Manuel Perez Encinas, Jorge Labrador, Delfim Duarte, Tomás Rivero Equiza, Olga Salamero, Rafael Colmenares, Maria Teresa Cedena Romero, Tamara Castaño, Anna Armatys, Alberto Giménez Conca, Cristina Gil, Teresa Olave, Lorenzo Algarra, María García-Fortes, Juan Miguel Bergua Burgues, Gabriela Rodriguez Macias, Manuel Barrios García, Eduardo Rodríguez-Arbolí, Teresa Caballero-Velazquez, Dunia De Miguel, Fernanda Trigo, Joana Brioso Infante, Emilia Ulenberg, Bruno Paiva, Virginia Pradillo Fernandez, Mar Tormo, Victor Noriega Concepción, Teresa Bernal Del Castillo, Rolando Omar Vallansot, Mercedes Colorado, Lisette Costilla-Barriga, Matxalen Olivares Salaverri, Isabel Simón-Pilo, Nerea Caminos, Ada Esteban-Figuerola, Małgorzata Sobczyk-Kruszelnicka, Renata Guzicka-Kazimierczak, Krzysztof Lewandowski, Andrzej Szczepaniak, Santiago Cranco, Manuela Clavijo, Irene Rey, Magdalena Karasek, Antonio Solana-Altabella, Leticia Rapan, Marta Sobas, Pau Montesinos

Blood (2025) 146 (Supplement 1): 218.

https://doi.org/10.1182/blood-2025-218

Published: 2025

Journal Articles

Prognosis of FLT3 ligand level in newly diagnosed FLT3-ITD negative Acute Myeloid Leukemia patients enrolled in the pethema QUIWI trial

Blood (2025) 146 (Supplement 1): 1694.

https://doi.org/10.1182/blood-2025-1694

Published: 2025

Journal Articles

Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia: A european multicenter study of 171 patients

Blood (2025) 146 (Supplement 1): 1662.

https://doi.org/10.1182/blood-2025-1662

Published: 2025

Journal Articles

Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study

Blood (2025) 146 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2025-1001

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Safety and efficacy of surovatamig (AZD0486) in adolescent and adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): Updated Results from the Phase 1/2 SYRUS study

Excellent prognosis for adult patients with Philadelphia chromosome-negative ALL with standard genetic risk and EARLY clearance of MRD. sub-analysis of pethema LAL19 trial

Clinical impact of FLT3 microclones on outcomes in patients with newly diagnosed FLT3-ITD negative AML: A subanalysis from the pethema quiwi trial

Real-world insights into venetoclax and/or hypomethylating agent discontinuation in patients with Acute Myeloid Leukemia

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed AML with CBFB::MYH11 or RUNX1::RUNX1T1 fusions: Real-world outcomes based on international registry data

Identifying patients with indolent Acute Myeloid Leukemia: Long term survivors after best supportive care only, results from the pethema registry

Crenolanib plus salvage chemotherapy improves outcomes in FLT3-mutant and NPM1 co-mutated relapsed/ refractory (R/R) Acute Myeloid Leukemia (AML): Results from a randomized, placebo-controlled, double-blind trial

Monotherapy update from Phase 1 portion in Phase1/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia

Efficacy and safety of pivekimab sunirine in combination with venetoclax plus azacitidine in unfit patients with newly diagnosed Acute Myeloid Leukemia

Impact of molecular profile and variant allele frequency in patients with Acute Myeloid Leukemia undergoing allogeneic transplantation in first remission: A study by the pethema group

CYP3A4 inhibitors (CYP3A4i) and myelosuppression in patients (Pts) with newly diagnosed mutant isocitrate dehydrogenase 1 (mIDH1) Acute Myeloid Leukemia (AML) in the phase 3 AGILE study

Analysis of hematologic improvement (HI) by time to response in Relapsed/Refractory Acute Myeloid Leukemia (AML) patients treated with olutasidenib

Real world outcomes in 355 patients with Acute Myeloid Leukemia arising from chronic myelomonocytic leukemia: A multinational retrospective study

Phase 1 study of revumenib in combination with intensive chemotherapy (IC) in patients (Pts) with newly diagnosed (ND) Acute Myeloid Leukemia (AML) harboring genetic alterations in KMT2A, NPM1, or NUP98: SNDX-5613-0708

Preliminary results from RIVER-81, a phase 2 study of romaciclib (RVU120) + venetoclax in patients with acute myeloid leukemia failing first-line venetoclax + hypomethylating agent (HMA)

Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study

Disease presentation and immunophenotype characteristics in 257 patients with blastic plasmacytoid dendritic cell neoplasm: A pethema/PALG study

Prognosis of FLT3 ligand level in newly diagnosed FLT3-ITD negative Acute Myeloid Leukemia patients enrolled in the pethema QUIWI trial

Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia: A european multicenter study of 171 patients

Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only